Standard BioTools Inc. (LAB) Quick Ratio
- Quick ratio · latest quarter: Value 8.67×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 8.67× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $492.47M ÷ $56.80M ≈ 8.67× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 492.47M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 56.80M USD | Liabilities, Current |
| Cash and equivalents | 270.03M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 206.69M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 15.75M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 17.10M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $492.47M | $56.80M | $270.03M | $206.69M | $15.75M | $17.10M | 8.67× |
| 2026-03-31 | $471.81M | $42.20M | $265.77M | $189.40M | $16.64M | $18.59M | 11.18× |
| 2025-12-31 | $201.01M | $108.31M | $120.86M | $66.71M | $13.43M | $19.98M | 1.86× |
| 2025-09-30 | $208.44M | $107.97M | $129.42M | $65.48M | $13.54M | $25.42M | 1.93× |
| 2025-06-30 | $251.70M | $98.02M | $158.62M | $78.47M | $14.61M | $24.17M | 2.57× |
| 2025-03-31 | $293.54M | $56.24M | $150.88M | $107.18M | $35.48M | $42.13M | 5.22× |
| 2024-12-31 | $326.48M | $65.89M | $166.73M | $126.15M | $33.61M | $40.74M | 4.95× |
| 2024-09-30 | $401.65M | $120.61M | $210.65M | $155.68M | $35.32M | $42.64M | 3.33× |
| 2024-06-30 | $427.15M | $123.81M | $269.81M | $124.90M | $32.44M | $42.62M | 3.45× |
| 2024-03-31 | $498.29M | $121.55M | $287.06M | $175.22M | $36.01M | $40.36M | 4.10× |
| 2023-12-31 | $134.56M | $109.33M | $51.70M | $63.19M | $19.66M | $20.53M | 1.23× |
| 2023-09-30 | $145.41M | $51.80M | $79.66M | $49.20M | $16.56M | $21.93M | 2.81× |
| 2023-06-30 | $157.42M | $46.84M | $142.30M | $0.00 | $15.12M | $22.08M | 3.36× |
| 2023-03-31 | $169.04M | $43.79M | $113.66M | $40.87M | $14.50M | $22.51M | 3.86× |
| 2022-12-31 | $183.06M | $43.44M | $81.31M | $84.47M | $17.28M | $21.47M | 4.21× |
| 2022-09-30 | $202.46M | $46.17M | $60.20M | $124.97M | $17.29M | $21.95M | 4.39× |
| 2022-06-30 | $222.15M | $42.77M | $74.36M | $136.85M | $10.94M | $22.79M | 5.19× |
| 2022-03-31 | (m) | $47.17M | $29.98M | (m) | $15.42M | $23.25M | (m) |
| 2021-12-31 | (m) | $49.57M | $28.45M | (m) | $18.32M | $20.82M | (m) |
| 2021-09-30 | (m) | $47.29M | $29.31M | (m) | $13.73M | $24.50M | (m) |
| 2021-06-30 | (m) | $52.85M | $30.86M | (m) | $15.67M | $25.07M | (m) |
| 2021-03-31 | (m) | $53.53M | $49.74M | (m) | $15.41M | $21.89M | (m) |
| 2020-12-31 | (m) | $54.25M | $68.52M | (m) | $25.42M | $19.69M | (m) |
| 2020-09-30 | (m) | $42.79M | $72.34M | (m) | $17.61M | $19.56M | (m) |
| 2020-06-30 | (m) | $38.35M | $42.97M | (m) | $9.98M | $18.90M | (m) |
| 2020-03-31 | (m) | $35.36M | $34.99M | (m) | $14.41M | $16.29M | (m) |
| 2019-12-31 | (m) | $32.82M | $21.66M | (m) | $18.98M | $13.88M | (m) |
| 2019-09-30 | (m) | $33.37M | $25.89M | (m) | $14.01M | $15.00M | (m) |
| 2019-06-30 | (m) | $37.32M | $24.05M | (m) | $19.26M | $14.27M | (m) |
| 2019-03-31 | (m) | $34.18M | $65.63M | (m) | $19.31M | $13.75M | (m) |
| 2018-12-31 | (m) | $37.58M | $95.40M | (m) | $16.65M | $13.00M | (m) |
| 2018-09-30 | (m) | $38.87M | $35.83M | (m) | $18.38M | $15.42M | (m) |
| 2018-06-30 | (m) | $36.65M | $39.42M | (m) | $16.87M | $15.25M | (m) |
| 2018-03-31 | (m) | $33.70M | $41.97M | (m) | $16.27M | $15.25M | (m) |
| 2017-12-31 | (m) | $33.47M | $58.06M | (m) | $15.05M | $15.09M | (m) |
| 2017-09-30 | (m) | $31.88M | $60.94M | (m) | $13.73M | $17.75M | (m) |
| 2017-06-30 | (m) | $34.32M | $39.60M | (m) | $13.66M | $18.77M | (m) |
| 2017-03-31 | (m) | $31.29M | $44.10M | (m) | $14.39M | $19.71M | (m) |
| 2016-12-31 | (m) | $29.50M | $35.05M | (m) | $14.61M | $20.11M | (m) |
| 2016-09-30 | (m) | $27.91M | $32.31M | (m) | $12.84M | $20.84M | (m) |
| 2016-06-30 | (m) | $32.31M | $35.90M | (m) | $18.89M | $18.18M | (m) |
| 2016-03-31 | (m) | $30.52M | $42.85M | (m) | $19.64M | $19.57M | (m) |
| 2015-12-31 | (m) | $30.08M | $29.12M | (m) | $25.46M | $17.92M | (m) |
| 2015-09-30 | (m) | $27.48M | $28.82M | (m) | $26.25M | $19.14M | (m) |
| 2015-06-30 | (m) | $28.93M | $23.75M | (m) | $21.79M | $18.82M | (m) |
| 2015-03-31 | (m) | $24.90M | $36.98M | (m) | $19.58M | $17.39M | (m) |
| 2014-12-31 | (m) | $29.39M | $33.71M | (m) | $22.38M | $15.99M | (m) |
| 2014-09-30 | (m) | $27.31M | $30.94M | (m) | $16.92M | $16.96M | (m) |
| 2014-06-30 | (m) | $27.31M | $43.68M | (m) | $13.33M | $16.36M | (m) |
| 2014-03-31 | (m) | $25.74M | $101.02M | (m) | $18.79M | $13.43M | (m) |
| 2013-12-31 | (m) | $17.95M | $35.26M | (m) | $10.55M | $8.15M | (m) |
| 2013-09-30 | (m) | $15.04M | $20.10M | (m) | $12.41M | $8.02M | (m) |
| 2013-06-30 | (m) | $11.63M | $32.29M | (m) | $10.84M | $7.23M | (m) |
| 2013-03-31 | (m) | $11.54M | $61.81M | (m) | $10.06M | $7.37M | (m) |
| 2012-12-31 | (m) | $11.60M | $58.65M | (m) | $12.90M | $7.17M | (m) |
| 2012-09-30 | (m) | $13.13M | $66.01M | (m) | $10.65M | $7.22M | (m) |
| 2012-06-30 | (m) | $14.77M | $9.85M | (m) | $9.61M | $6.61M | (m) |
| 2012-03-31 | (m) | $17.74M | $8.50M | (m) | $9.76M | $6.44M | (m) |
| 2011-12-31 | (m) | $20.17M | $13.55M | (m) | $9.25M | $5.97M | (m) |
| 2011-09-30 | $67.90M | $19.66M | $11.88M | $47.05M | $8.97M | $5.84M | 3.45× |
| 2011-06-30 | $74.67M | $17.76M | $10.13M | $54.22M | $10.32M | $4.85M | 4.20× |
| 2011-03-31 | (m) | (m) | $55.83M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $13.82M | $18.51M | $5.72M | $0.00 | $8.10M | $4.89M | 0.75× |
| 2010-09-30 | (m) | (m) | $5.08M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $8.07M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $14.60M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $17.80M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |